Cases & Deals

  • Home
  • Practices
  • Aventis Pharmaceuticals successfully defends against monopolization claims based on fraud on the Patent Office theory

Share

Aventis Pharmaceuticals successfully defends against monopolization claims based on fraud on the Patent Office theory

December 2013

Client(s) sanofi-aventis S.A.

Jones Day resolved class action claims that Aventis Pharmaceuticals, the exclusive licensee of patents covering DDAVP (a treatment for certain water metabolism disorders), knew that the licensor obtained those patents by fraud before the Patent and Trademark Office.

In re DDAVP Direct Purchaser Antitrust Litigation, 585 F.3d 677 (2d Cir. 2009); No. 05-cv-2237 (S.D.N.Y. 2006)

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.